Navigation Links
Cell Therapeutics Retires Remaining Convertible Debt
Date:12/18/2011

SEATTLE, Dec. 19, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it has deposited $11.2 million in cash as trust funds with U.S. Bank National Association, as the trustee of the outstanding 5.75% convertible senior notes (the "Notes"), which is an amount sufficient to pay and discharge the entire amount due on the Notes, including accrued and unpaid interest. CTI has now retired all of its outstanding convertible debt.

"We have worked diligently over the past five years to restructure, exchange, and retire all of our convertible debt while continuing to advance our product candidates toward market. The deleveraging of our balance sheet puts CTI in a stronger financial position as we ready for potential product approval in 2012," stated Louis A. Bianco, Chief Financial Officer of CTI.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com http://www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_alert

This press release includes forward-looking statements that involve a number of risks and uncertainties the outcome of which could materially and/or adversely affect actual future results and the market price of CTI's securities. Specifically, the risks and uncertainties that could affect the development of CTI's product candidates include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with pixantrone in particular, including, without limitation, the potential failure of pixa
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Amsterdam Molecular Therapeutics Announces Negative Equity Position
2. Fate Therapeutics Announces the Appointment of William H. Rastetter as Chairman of its Board of Directors and Interim CEO
3. Tarsa Therapeutics Targets 2012 NDA Submission for its OSTORA™ Oral Calcitonin
4. Stemline Therapeutics, Inc. to Present at the Oppenheimer 22nd Annual Healthcare Conference
5. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
6. MarketsandMarkets: Chronic Lymphocytic Leukemia Therapeutics Market Worth $2.2 Billion by 2020
7. Stemline Therapeutics, Inc. Announces Two Poster Presentations of SL-401 Efficacy Data Against Lymphoid Cancers at the 53rd Annual Meeting of the American Society of Hematology (ASH)
8. Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
9. MarketsandMarkets: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020
10. Aratana Therapeutics Completes $15 Million Series B Financing
11. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)...  Kainos Capital, a firm specializing in acquiring and ... has acquired the Slim-Fast brand from Unilever. Unilever will ... the transaction were not disclosed. Slim-Fast is ... markets ready-to-drink shakes, powders, bars and snacks to retail ... in the United Kingdom and ...
(Date:7/10/2014)... Adelaide research may help in the fight against terrorism ... tiny quantities of explosives with the use of light ... Sensors and Actuators B: Chemical , the researchers ... explosives in concentrations as low as 6.3 ppm (parts ... a few minutes. , "Traditionally explosives detection has involved ...
(Date:7/10/2014)... RICHLAND, Wash. The lithium-ion batteries that power our ... run longer on a single charge with the help ... the porous material to replace the graphite traditionally used ... more than 10 times the energy storage capacity of ... lithium-ion battery electrode was published today in Nature ...
(Date:1/15/2014)... a club sandwich at the nanoscale, National Institute ... in crafting a uniform, multi-walled carbon-nanotube-based coating that ... in upholstered furniture and other soft furnishings. , ... reduced 35 percent compared with untreated foam. As ...
Breaking Biology Technology:Kainos Capital Acquires Slim-Fast From Unilever 2Detecting trace amounts of explosives with light 2Silicon sponge improves lithium-ion battery performance 2Silicon sponge improves lithium-ion battery performance 3Layered security: Carbon nanotubes promise improved flame-resistant coating 2
... David P. Wright, Co-Chair of the Alliance for ... testified today before the House Labor, Health and ... critical importance of developing drugs, vaccines and other ... and other catastrophic health emergencies. Effective medical countermeasures ...
... to Enable BBK Worldwide to Better Serve Asia-Pacific ... BBK Worldwide, a global leader in patient recruitment ... BBK Worldwide -- Osaka, G.K., in Osaka, Japan. ... pharmaceutical, biotechnology, and medical device companies, as well ...
... 18 Sopherion Therapeutics, LLC, a biopharmaceutical company ... therapies, announced that it completed enrollment in its ... (Myocet(TM)) in metastatic HER-2-overexpressing breast cancer. This ... lead product in combination with the current standard ...
Cached Biology Technology:Alliance for Biosecurity Testifies Before Congress on Funding for Medical Countermeasure Development 2Forward-Thinking Patient Recruitment Company Poised to Create Bridges Between Japanese Clinical R&D Industry and Global Clinical Trial Marketplace 2Forward-Thinking Patient Recruitment Company Poised to Create Bridges Between Japanese Clinical R&D Industry and Global Clinical Trial Marketplace 3Sopherion Therapeutics Announces Completion of Enrollment in Phase III Study of Myocet in Metastatic Breast Cancer 2Sopherion Therapeutics Announces Completion of Enrollment in Phase III Study of Myocet in Metastatic Breast Cancer 3
(Date:7/11/2014)... This news release is available in German . ... imaging is a method that uses the refraction of ... absorption. The images produced with this method are often ... The scientists in the team of Prof. Franz Pfeiffer ... X-ray imaging and therapy including X-ray phase-contrast imaging. ...
(Date:7/11/2014)... develop relationships with other group members to reduce aggression ... baboons the strategy for grooming activities shows a certain ... in the scientific journal Biology Letters . , ... not practiced without ulterior motives. To be groomed has ... while grooming another individual can provide access to infants, ...
(Date:7/11/2014)... transplantation of mesenchymal stem cells can stimulate neurogenesis in ... Alzheimer,s disease (AD) and improve tissue and function injury ... reported on the therapeutic effect of adipose-derived stem cells ... effect on oxidative injury and neurogenesis in the brain ... School of Life Sciences, Tsinghua University, China transplanted ADSCs ...
Breaking Biology News(10 mins):New simple setup for X-ray phase contrast 2Baboons groom early in the day to get benefits later 2
... predicted that tree species will respond to global warming ... a new study of 65 different species in 31 ... Nearly 80 percent of the species aren,t yet ... staying in place -- but speeding up their life ...
... Nio Southern Oscillation (ENSO), altering the cycles of El Nio ... to Australia and many other Pacific-rim countries., New research published ... has revealed how the ENSO cycle has changed over the ... an impact on the strength and timing of El Nio ...
... of multiple sclerosis, a debilitating disease that affects up to ... researchers and medical professionals for generations. But Steven Schutzer, a ... now found an important clue why progress has been slow ... MS has focused on the wrong part of the brain. ...
Cached Biology News:Climate change may speed up forests' life cycles 2Global warming could change strength of El Niño 2Multiple sclerosis appears to originate in different part of brain than long believed 2Multiple sclerosis appears to originate in different part of brain than long believed 3
... gun system, 100-120 V, is used for ... This handheld device employs an adjustable helium ... biomaterial-coated gold microcarriers from the inner wall ... target cells. This system has a 2 ...
... Conjugated peptides, recombinant or native proteins are used ... immunization protocol optimized in time, quantity of antigen ... the use of 2 animals per protocol in ... yield on a 77-day protocol is approximately 75 ...
Mouse monoclonal antibody raised against a partial recombinant DHX8. NCBI Entrez Gene ID = DHX8...
... binding specificity and signaling of the members ... be modified by alternative splicing--which has important ... you can perform a classical expression profiling ... different alternatively spliced forms of the gene ...
Biology Products: